LILRB4 is highly expressed during the early stages of plasma cell malignancy in MM (CD38 + CD138 + CD19 + CD56 +), and is considered a marker of aggressive proliferation in MM. This evidence concerns the gene LILRB4 and Miyoshi myopathy.